IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

EUROPEAN COMMISSION

Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 December 2012 to 31 December 2012

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2013/C 24/01)

[1] OJ L 136, 30.4.2004, p. 1.

— **Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
18.12.2012	NexoBrid	Concentrate of proteolytic enzymes enriched in bromelain	TEVA Pharma GmbH Graf-Arco-Str. 3, 89079 Ulm, Deutschland	EU/1/12/803	Powder and gel for gel	Pending	20.12.2012
20.12.2012	Betmiga	mirabegron	Astellas Pharma Europe B.V. Elisabethhof 19, 2353 EW Leiderdorp, Nederland	EU/1/12/809	Prolonged-release tablet	G04BD12	7.1.2013

— **Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
10.12.2012	Olanzapine Glenmark	Glenmark Generics (Europe) Limited Laxmi House, 2-B Draycott Avenue, Kenton, Harrow, Middlesex HA3 OBU, United Kingdom	EU/1/09/587	12.12.2012
10.12.2012	Olanzapine Glenmark Europe	Glenmark Generics (Europe) Limited Laxmi House, 2-B Draycott Avenue, Kenton, Harrow, Middlesex HA3 OBU, United Kingdom	EU/1/09/588	12.12.2012
10.12.2012	Sifrol	Boehringer Ingelheim International GmbH Binger Strasse 173, D-55216 Ingelheim am Rhein, Deutschland	EU/1/97/050	12.12.2012
17.12.2012	Avamys	Glaxo Group Ltd Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/07/434	19.12.2012
17.12.2012	Clopidogrel Zentiva	sanofi-aventis groupe 54, rue La Boétie, 75008 Paris	EU/1/08/465	19.12.2012
17.12.2012	Januvia	Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/07/383	19.12.2012
18.12.2012	Actos	Takeda Global Research and Development Centre (Europe) Ltd 61 Aldwych, London WC2B 4AE, United Kingdom	EU/1/00/150	20.12.2012
18.12.2012	Afinitor	Novartis Europharm Ltd Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/09/538	21.12.2012
18.12.2012	Arava	Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Deutschland	EU/1/99/118	20.12.2012
18.12.2012	Efficib	Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/08/457	20.12.2012
18.12.2012	Glubrava	Takeda Global Research and Development Centre (Europe) Ltd 61 Aldwych, London WC2B 4AE, United Kingdom	EU/1/07/421	20.12.2012
18.12.2012	Glustin	Takeda Global Research and Development Centre (Europe) Ltd 61 Aldwych, London WC2B 4AE, United Kingdom	EU/1/00/151	20.12.2012

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
18.12.2012	Janumet	Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/08/455	20.12.2012
18.12.2012	Leganto	UCB Manufacturing Ireland Ltd. Shannon Industrial Estate, Co, Clare, Ireland	EU/1/11/695	20.12.2012
18.12.2012	Pritor	Bayer Pharma AG 13342 Berlin, Deutschland	EU/1/98/089	20.12.2012
18.12.2012	Ristaben	Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/10/621	20.12.2012
18.12.2012	Ristfor	Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/10/620	20.12.2012
18.12.2012	TachoSil	Nycomed Austria GmbH St.-Peter-Strasse 25, A-4020 Linz, Österreich	EU/1/04/277	20.12.2012
18.12.2012	Thalidomide Celgene	Celgene Europe Limited 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, United Kingdom	EU/1/08/443	20.12.2012
18.12.2012	Velmetia	Merck Sharp & Dohme Ltd. Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/08/456	20.12.2012
18.12.2012	Xelevia	Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/07/382	20.12.2012
18.12.2012	Zytiga	Janssen-Cilag International NV Turnhoutseweg 30, B-2340 Beerse, België	EU/1/11/714	20.12.2012
20.12.2012	Adenuric	Menarini International Operations Luxembourg S.A. 1, Avenue de la Gare, L-1611 Luxembourg, Luxembourg	EU/1/08/447	24.12.2012
20.12.2012	Competact	Takeda Global Research and Development Centre (Europe) Ltd 61 Aldwych, London WC2B 4AE, United Kingdom	EU/1/06/354	24.12.2012
20.12.2012	Effentora	Teva Pharma B.V. Computerweg 10, DR Utrecht 3542, Nederland	EU/1/08/441	27.12.2012

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
20.12.2012	Exjade	Novartis Europharm Ltd Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/06/356	2.1.2013
20.12.2012	Extavia	Novartis Europharm Ltd Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom	EU/1/08/454	21.12.2012
20.12.2012	Kinzalmono	Bayer Pharma AG Berlin 13342, Deutschland	EU/1/98/091	2.1.2013
20.12.2012	Leflunomide Winthrop	Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Deutschland	EU/1/09/604	27.12.2012
20.12.2012	Micardis	Boehringer Ingelheim International GmbH Binger Strasse 173- D - 55216 Ingelheim am Rhein, Deutschland	EU/1/98/090	27.12.2012
20.12.2012	Prevenar 13	Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/09/590	2.1.2012
20.12.2012	Tesavel	Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/07/435	2.1.2013
20.12.2012	Viramune	Boehringer Ingelheim International GmbH Binger Strasse 173- D - 55216 Ingelheim am Rhein, Deutschland	EU/1/97/055	27.12.2012
20.12.2012	Zelboraf	Roche Registration Limited 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom	EU/1/12/751	2.1.2013

— **Suspension of a marketing authorization (Article 20 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
6.12.2012	Ribavirin Teva	Teva Pharma B.V. Computerweg 10, 3542 DR Utrecht, Nederland	EU/1/09/509	11.12.2012
6.12.2012	Ribavirin Teva Pharma BV	Teva Pharma B.V. Computerweg 10, 3542 DR Utrecht, Nederland	EU/1/09/527	11.12.2012

— **Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]): Accepted**

Date of the Décision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
6.12.2012	Contacera	Meloxicam	Pfizer Limited Ramsgate Road, Sandwich, Kent CT13 9NJ United Kingdom	EU/2/12/144	Solution for injection	QM01AC06	11.12.2012

[1] OJ L 136, 30.4.2004, p. 1.

— **Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
6.12.2012	Coxevac	CEVA SANTE ANIMALE 10 avenue de la Ballastière, 33500 Libourne, France	EU/2/10/110	11.12.2012
10.12.2012	Metacam	Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim am Rhein, Deutschland	EU/2/97/004	12.12.2012
10.12.2012	Nobilis Influenza H5N2	Intervet International B.V. Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland	EU/2/06/061	12.12.2012
10.12.2012	Procox	Bayer Animal Health GmbH 51368 Leverkusen, Deutschland	EU/2/11/123	12.12.2012
18.12.2012	Rheumocam	Chanelle Pharmaceuticals Manufacturing Limited Loughrea, Co. Galway, IRELAND	EU/2/07/078	20.12.2012

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus,
Canary Wharf
UK-LONDON E14 4H